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IMPORTANCE Controlled studies have shown short-term efficacy of esketamine for
treatment-resistant depression (TRD), but long-term effects remain to be established.
OBJECTIVE To assess the efficacy of esketamine nasal spray plus an oral antidepressant
compared with an oral antidepressant plus placebo nasal spray in delaying relapse of
depressive symptoms in patients with TRD in stable remission after an induction and
optimization course of esketamine nasal spray plus an oral antidepressant.
DESIGN, SETTING, AND PARTICIPANTS In this phase 3, multicenter, double-blind, randomized
withdrawal study conducted fromOctober 6, 2015, to February 15, 2018, at outpatient
referral centers, 705 adults with prospectively confirmed TRDwere enrolled; 455 entered the
optimization phase and were treated with esketamine nasal spray (56 or 84mg) plus an oral
antidepressant. After 16 weeks of esketamine treatment, 297 who achieved stable remission
or stable response entered the randomized withdrawal phase.
INTERVENTIONS Patients who achieved stable remission and those who achieved stable
response (without remission) were randomized 1:1 to continue esketamine nasal spray or
discontinue esketamine treatment and switch to placebo nasal spray, with oral
antidepressant treatment continued in each group.
MAIN OUTCOMES ANDMEASURES Time to relapse was examined in patients who achieved
stable remission, as assessed using a weighted combination log-rank test.
RESULTS Amongthe297adults(meanage[SD],46.3[11.13]years; 197[66.3%]female)whoentered
the randomizedmaintenancephase, 176 achieved stable remission; 24 (26.7%) in the esketamine
andantidepressant groupand39 (45.3%) in the antidepressant andplacebogroupexperienced
relapse (log-rankP = .003, numberneeded to treat [NNT],6). Among the 121whoachieved stable
response, 16 (25.8%) in theesketamine andantidepressant groupand34 (57.6%) in the
antidepressantandplacebogroupexperiencedrelapse(log-rankP < .001,NNT,4).Esketamineand
antidepressant treatmentdecreased the risk of relapseby51%(hazard ratio [HR],0.49;95%CI,
0.29-0.84)amongpatientswhoachievedstable remissionand70%(HR,0.30;95%CI,0.16-0.55)
amongthosewhoachievedstableresponsecomparedwithantidepressantandplacebotreatment.
Themost commonadverse events reported for esketamine-treatedpatients after randomization
weretransientdysgeusia,vertigo,dissociation,somnolence,anddizziness(incidence,20.4%-27.0%),
each reported in fewerpatients (<7%) treatedwith anantidepressant andplacebo.
CONCLUSIONSANDRELEVANCE ForpatientswithTRDwhoexperienced remissionor response
after esketamine treatment, continuationof esketaminenasal spray in addition tooral
antidepressant treatment resulted in clinicallymeaningful superiority indelaying relapse
comparedwith antidepressant plusplacebo.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02493868
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D epression is the leading cause of disability worldwideand is associated with a 10-year reduction in lifeexpectancy.1,2Achievingandmaintainingremission,the
goalsof treatment for this recurrentdisease, improves function-
ing, reduces suicide risk, and leads to greater clinical stability.3
Patientswhohave not responded to at least 2 different antide-
pressantsinthecurrentdepressiveepisodeareconsideredtohave
treatment-resistantdepression(TRD).4Patientswithtreatment-
resistantmajordepressivedisorder (MDD)experiencerelapseat
ahigherratethandothosewithtreatment-responsiveMDD.Even
whenpatientswithTRDrespondtotreatment,theoverall relapse
ratewhile continuing treatmentwith the same antidepressant
ishighafter2 (65%;within3.1months) and3 failed trials (71.1%;
within3.3months).3There isasubstantialunmetneedforeffec-
tive treatments that cansustainantidepressantbenefits for the
populationwith TRD.
Several short-term studies5-12with racemic ketamine and
a stereoisomer, esketamine, have demonstrated efficacy for
TRD. In contrast to available data about short-term antide-
pressanteffectsofesketamineandketamine,13,14 little isknown
aboutmaintaining antidepressant effects in the long term.We
report the findings of, to our knowledge, the first controlled
maintenancestudyofesketamine that evaluatedwhether con-
tinued use of intermittently administered esketamine nasal
spray plus an oral antidepressant can sustain antidepressant
effects among patients with TRD to a greater extent than an
oral antidepressant alone.
Methods
Study Population
Patientswereenrolleddirectlyorweretransferredintothisstudy
afterachieving treatment response (≥50%reduction frombase-
line inMontgomery-Åsberg Depression Rating Scale [MADRS]
totalscore) toesketaminenasalsprayin1of2short-termdouble-
blind,active-controlledstudies (1 fixeddoseand1 flexibledose),
with all patients meeting identical entrance criteria (reported
elsewhere12,15. Participantswereoutpatientswhowere in treat-
mentorreferredtoavarietyofacademicandnonacademicclinic
settingsacross theUnitedStates,Canada, andEurope.Enrolled
patients were approached by their treating physician or re-
sponded to institutional review board– or independent ethics
committee–approvedpatientrecruitmentmaterials. Inaddition,
aweb-based prescreening tool was developed to assist sites in
identifying appropriate study candidates.
ThetrialprotocolcanbefoundinSupplement1. Institutional
reviewboardsand independentethics committees (eAppendix
1 in Supplement 2) approved the study protocol and amend-
ments.Thestudywasconductedinaccordancewithethicalprin-
ciples of the Declaration of Helsinki,16 Good Clinical Practices,
and applicable regulatory requirements. All patients provided
written informed consent before entering the study.
Eligible patients (aged 18-64years) had recurrent or single-
episode(≥2years)MDD(DSM-5),17a totalscoreof34orhigheron
theClinician-RatedInventoryofDepressiveSymptomatology,18
anda totalMADRSscoreof28orhigher, indicatingmoderate to
severedepression.Atscreening,allpatientswerenonresponders
to at least 1, but nomore than 5, antidepressants in the current
depressiveepisode,withnonresponse toadifferentoralantide-
pressant confirmed by 4weeks ormore of observed treatment
during theprospectivescreeningphase.12Keyexclusioncriteria
werehistoryofpsychoticdisorder, suicidalbehaviorwithin the
prioryear, currentor recenthomicidalor suicidal ideationor in-
tent,diagnosisofMDDwithpsychotic features,andmoderateor
severesubstanceoralcoholusedisorderwithin6months.Ahis-
tory (lifetime)ofketamineusedisorderwasexclusionary. (A full
listof theinclusionandexclusioncriteria ispresentedineAppen-
dix 2 in Supplement 2.) Urine drug screening (eg, barbiturates,
methadone,opiates,cocaine,cannabinoids,phencyclidine,and
amphetamine ormethamphetamine)was conducted intermit-
tently before dosing throughout the study.
Study Design
This double-blind, randomized clinical trial (A Study of Intra-
nasal EsketaminePlus anOralAntidepressant forRelapsePre-
vention in Adult Participants With Treatment-Resistant De-
pression [SUSTAIN-1]) used a randomizedwithdrawal design
andwasconducted fromOctober6, 2015, toFebruary 15, 2018.
Ninety-nine sites randomized patients.
The study consisted of up to 5 phases: (1) a 4-week screen-
ing and prospective observation phase (direct-entry patients
only); (2) a4-weekopen-label inductionphase (direct-entrypa-
tientsonly); (3)a12-weekoptimizationphase(open-label,direct-
entry patients or double-blind, transfer-entry patients); (4) a
maintenance phase (double-blind, randomized withdrawal,
eventdriven,variableduration);and(5)a2-weekposttreatment
follow-upphase. The studycontinueduntil the requisitenum-
berofrelapsesoccurred,specifiedbyapreplannedinterimanaly-
sis (described below).
Direct-Entry Patients
During the 4-week screening and observation phase, nonre-
sponse to the ongoing oral antidepressant treatment was as-
sessed prospectively in eligible patients. Those with nonre-
sponse at the end of this phase discontinued use of the prior
antidepressant(s),with theoptionof a 3-weekor less taper pe-
riod. In the inductionphase, patients receivedesketaminena-
sal spray (56or84mg, flexiblydosed) twiceweeklyplus anew
Key Points
Question What are the long-term effects of esketamine nasal
spray in patients with treatment-resistant depression?
Findings Of the 297 adults with treatment-resistant depression
whowere randomized in themaintenance phase of this clinical
trial, those who continued treatment with intermittently
administered esketamine nasal spray plus an oral antidepressant
had a significantly delayed time to relapse vs those treated with
oral antidepressant plus placebo nasal spray after 16 weeks of
initial treatment with esketamine and an antidepressant.
Meaning Continued treatment with esketamine nasal spray plus
an antidepressant can sustain antidepressant effects among
patients with treatment-resistant depression to a greater extent
than an oral antidepressant alone.
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oral antidepressant (duloxetine, escitalopram, sertraline,
or extended-release venlafaxine) administered daily.
Transfer-Entry and Direct-Entry Patients
Transfer-entry and direct-entry patients who achieved treat-
ment response at the end of the induction phase (ie, ≥50% re-
duction inMADRS score frombaseline) entered a 12-weekop-
timization phase duringwhich study drug dosages at the end
of the inductionphase remained fixedbut the frequencyof in-
tranasal dosingwas reduced to onceweekly for 4weeks then
individualized toweekly or every 2weeks basedon the sever-
ityofdepressive symptoms.Topreserve theblinding, transfer-
entry patients continued treatment assignment (esketamine
or placebo) from the induction phase.
Maintenance Phase
At week 16 of the optimization phase, esketamine-treated
direct-entry (open-label treatment) and transfer-entry pa-
tients (double-blind treatment) who had achieved stable re-
mission (primary analysis set; defined asMADRS score ≤12 for
≥3 of the last 4 weeks, with 1 excursion [MADRS score >12] or
1missingMADRS assessment permitted atweek 13 or 14 only)
andpatientswith stable response (secondary analysis set; de-
fined as ≥50% reduction inMADRS score frombaseline in the
last 2 weeks of the optimization phase but without achieving
remission) continued into themaintenancephase.Becausepa-
tients with treatment resistance who achieve remission re-
portedly have lower relapse rates compared with those who
respondbutdonotexperience remission,3 theprespecifiedpri-
maryanalysiswasconductedusing theanalysisofpatientswho
achieved stable remission. However, those who met the less
conservative criteria for stable response (butnot stable remis-
sion)were also evaluatedbecause a reduction inMADRSscore
frombaselineof 50%ormore for 2weeks in this patient popu-
lation is considered as clinically meaningful. Patients who
achieved stable remission and those who achieved stable re-
sponse (without remission)were separately randomized 1:1 ac-
cording to a computer-generated schedule to continue esket-
amine treatment or discontinue esketamine treatment and
switch to placebo nasal spray, each in addition to oral antide-
pressant treatment. The dosage of antidepressant through-
out themaintenancephase remainedunchanged from the in-
duction phase. Randomizationwas balanced using randomly
permuted blocks and stratified by country.
Transfer-entrypatientswhowereassignedtotheantidepres-
sant and placebo group in the short-term studies and achieved
stableremissionorstableresponsecontinuedthesametreatment
inthemaintenancephaseandwereincludedinsafety,butnotef-
ficacy,analysesofthisstudy.Treatmentadministrationfrequency
during themaintenancephasewasbasedonanalgorithmusing
theMADRS score andwas reevaluated every 4weeks,with na-
sal spray treatment self-administeredeither onceweeklyor ev-
ery 2weeks.
Patientswhomet thecriteria forexperiencingrelapsecould
proceedintoalong-termsafetystudyofesketaminenasalspray.19
Otherwise,patientscontinuedtoa2-weekposttreatmentfollow-
up phase after their participation in the maintenance phase
ended.
Intranasal Study Drug and Administration
Esketamine andplacebowere provided innasal spraydevices,
eachcontaining200μLofsolutionperdevice (ie,2sprays).Each
devicecontained32.28mgofesketaminehydrochloride (28mg
ofesketaminebase)orplacebo.Theplacebosolutioncontained
abitteringagent (denatoniumbenzoate) tosimulate the tasteof
esketamine solution andmaintain the blinding.
Efficacy Assessments
Independent, blinded, remote raters performed MADRS
assessments throughout the study (weeks 1, 2, and 4 of
the screening and observation phase and weekly during
the induction, optimization, maintenance, and follow-up
phases).
Safety Assessments
Adverse events (AEs) and other safety assessments, includ-
ing clinical laboratory tests, physical examination, electro-
cardiography, Columbia Suicide Severity Rating Scale20
(C-SSRS) (with 0 indicating no suicidal ideation or behavior;
1-5, suicidal ideation; and 6-10, suicidal behavior; item
descriptions in eAppendix 3 in Supplement 2) were moni-
tored throughout the study. Vital signs, the Clinician-
Administered Dissociative States Scale21 (CADSS), and the
Brief Psychiatric Rating Scale22 (4-item positive symptom
subscale) were assessed at baseline and all treatment admin-
istration visits (before dosing and at 40 minutes, 1 hour
[vital signs only], and 1.5 hours after dosing).
The 20-item Physician Withdrawal Checklist23 was ad-
ministered to assess for potential withdrawal symptoms af-
ter cessation of intranasal study medication. Cognitive test-
ingwasperformedbeforedosing toassess for apotential effect
on cognition; these data will be reported in a separate article.
Statistical Analysis
Sample Size Determination
On the basis of assumptions (accrual period and rate, maxi-
mum study duration, and dropout rate), 211 patients who
achieved stable remission needed to be randomized (1:1 ra-
tio) toobtain84relapses,providing90%power todetect ahaz-
ard ratio (HR) of 0.49 at a 2-sided α of .05 for a fixed-sample
design to detect superiority of esketamine and antidepres-
sant over antidepressant and placebo in delaying relapse.
A 2-stage group-sequential design was implemented for the
analysis set of patientswhoachieved stable remission, and an
independent data-monitoring committee performed a pre-
specified interim analysis after 31 relapses to assess early ef-
ficacy.
The interim analysis on patients who achieved stable re-
mission did not show superiority of esketamine and antide-
pressant over antidepressant andplacebo (at a 2-sided signifi-
cance level of .0097, log-rank test); therefore, the study
continued, and the number of relapses in patients who
achieved stable remission was reestimated to 59 relapses in
total with an adjusted significance level of .046 (2-sided) for
the final efficacy analysis (based on theWang-Tsiatis bound-
ary α-spending function24), ensuring a conditional power of
90% or higher after the interim analysis.
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Efficacy End Points and Analyses
Cumulative distribution of time to relapse during the mainte-
nancephaseamongpatientswhoachievedstableremission(pri-
maryefficacyendpoint)andthosewhoachievedstableresponse
without remission (secondary endpoint)was estimatedby the
Kaplan-Meier method. Relapse was defined as a MADRS total
scoreof22orhigher for2consecutiveassessmentsseparatedby
5 to15daysorhospitalization forworseningdepression, suicide
attempt, suicide prevention or completed suicide, or another
clinically relevantevent suggestiveof relapse (assessedbya re-
lapse adjudication committee).
Thebetween-groupdifference in time to relapsewas ana-
lyzedusinga log-rank test (weightedcombination [interimand
final analyses] for patientswho achieved stable remission be-
cause of conducting an interim analysis). The estimated HRs
and95%CIswerebasedonweightedestimates forpatientswho
achieved stable remission and on a Cox proportional hazards
regression model with treatment as a factor for patients who
achieved stable response. A similar post hoc analysiswas per-
formed combining the analysis set of patients who achieved
stable remission and the analysis set of patientswhoachieved
stable response.
Results
A total of 297 adults (mean age [SD], 46.3 [11.13] years; 197
[66.3%] female) were randomized in the maintenance phase
of the study.ACONSORTdiagram ispresented inFigure 1. The
median number of patients per site was 2 (range, 1-25). The
treatmentgroupswerecomparablebasedondemographic and
baseline clinical characteristics (Table 1). Median exposure to
intranasal esketamineduring themaintenancephasewas 17.7
weeksamongpatientswhoachievedstable remissionand 19.4
Figure 1. CONSORTDiagram
1097 Patients assessed for eligibility
176 Patients with stable remissiona 121 Patients with stable responseb
800 Excluded
378 Screen failures
86 Transfer-entry antidepressant and
placebo
14 GCP issues
322 Withdrawn during the induction/
optimization phases
221 Did not meet criteria for 
continuing into the next phase
27 Adverse event
23 Patient withdrawal
14 MADRS total score ≥22 for 2
consecutive visits
10 Lack of efficacy
6 Protocol violation
3 Lost to follow-up
18 Other
297 Randomized
90 Randomized to
esketamine nasal spray
and oral antidepressant
0 Lost to follow-up
8 Discontinued
intervention
90 Included in analysis 86 Included in analysis
0 Lost to follow-up
9 Discontinued
intervention
86 Randomized to placebo
and oral antidepressant
62 Randomized to
esketamine nasal spray
and oral antidepressant
1 Lost to follow-up
4 Discontinued
intervention
62 Included in analysis 59 Included in analysis
0 Lost to follow-up
3 Discontinued
intervention
59 Randomized to placebo
and oral antidepressant
This study used data for those patients who had been undergoing treatment
with esketamine nasal spray plus an oral antidepressant for 16 weeks and who,
after meeting criteria for either stable remission (primary analysis) or stable
response (secondary analysis), were randomized (separately) to continue
treatment with esketamine nasal spray plus an oral antidepressant or to
discontinue treatment with esketamine and switch to placebo nasal spray and
continue use of the oral antidepressant. Stable remission was defined as a
Montgomery-Åsberg Depression Rating Scale (MADRS) total score of 12 or
lower for 3 or more of the last 4 weeks of the optimization phase, with up to 1
excursion (MADRS total score >12) or 1 missing MADRS assessment permitted at
week 13 or 14 only. Stable response was defined as 50% or greater reduction in
MADRS total score from baseline in the last 2 weeks of the optimization phase,
but without achieving stable remission criteria. Patients who were lost to
follow-up or discontinued treatment after randomization were included in the
analysis.
a One patient with stable response was incorrectly randomized in the group
with stable remission.
bOne patient who did not meet stable remission or stable response criteria at
the end of the optimization phase was incorrectly randomized in the group
with stable response.
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Table 1. Demographic and Baseline Characteristicsa
Characteristic
Stable Remission at Baseline Stable Response at Baseline
Esketamine Nasal Spray
and Oral Antidepressant
(n = 90)
Oral Antidepressant
and Placebo Nasal
Spray (n = 86)
Esketamine Nasal Spray
and Oral Antidepressant
(n = 62)
Oral Antidepressant
and Placebo Nasal
Spray (n = 59)
Age, mean (SD) [range], y 45.4 (12.12) [19-64] 46.2 (11.16) [19-64] 47.2 (11.00) [23-63] 46.7 (9.76) [24-64]
Sex
Male 32 (35.6) 27 (31.4) 24 (38.7) 17 (28.8)
Female 58 (64.4) 59 (68.6) 38 (61.3) 42 (71.2)
Race
American Indian or Alaskan Native 0 1 (1.2) 0 0
Asian 0 0 0 1 (1.7)
Black 4 (4.4) 6 (7.0) 2 (3.2) 1 (1.7)
White 80 (88.9) 76 (88.4) 57 (91.9) 55 (93.2)
Other 2 (2.2) 1 (1.2) 3 (4.8) 1 (1.7)
Multiple 1 (1.1) 0 0 1 (1.7)
Not reported 3 (3.3) 2 (2.3) 0 0
Region
Europe 52 (57.8) 50 (58.1) 34 (54.8) 35 (59.3)
North America 22 (24.4) 20 (23.3) 18 (29.0) 16 (27.1)
Brazil and Mexico 16 (17.8) 16 (18.6) 10 (16.1) 8 (13.6)
Age diagnosed with MDD, mean (SD) [range], y 32.5 (11.42) [5-55] 33.4 (11.41) [10-60] 36.2 (13.25) [15-61] 34.0 (10.54) [14-60]
Duration of current episode, mean (SD) [range], wk 112.2 (171.30) [12-1040] 110.5 (147.41) [9-884] 121.6 (193.85) [13-1080] 141.8 (254.43) [9-1248]
No. of previous antidepressants before screening
≤2 71 (78.9) 62 (73.8) 41 (66.1) 34 (57.6)
>2 19 (21.1) 22 (26.2) 21 (33.9) 25 (42.4)
History of suicidal ideation in previous 6 mo 18 (20.0) 14 (16.3) 20 (32.3) 14 (23.7)
Class of oral antidepressant
SNRI 62 (68.9) 58 (67.4) 35 (56.5) 36 (61.0)
SSRI 28 (31.1) 28 (32.6) 27 (43.5) 23 (39.0)
Baseline MADRS total score, mean (SD)
All patients 37.4 (5.20) 37.6 (4.66) 40.1 (5.56) 38.9 (4.92)
Direct-entry patientsb 37.8 (5.28) 37.8 (4.26) 40.5 (4.88) 38.5 (4.65)
Transfer-entry patientsc 36.8 (5.10) 37.3 (5.38) 39.6 (6.22) 39.9 (5.49)
Baseline PHQ-9 score, mean (SD) 19.2 (4.16) 19.8 (3.43) 20.5 (4.12) 20.4 (4.15)
Dose of esketamine before randomizationd
56 mg 40 (44.4) 33 (38.4) 20 (32.3) 19 (32.2)
Direct-entry patients 14 (15.6) 9 (10.5) 7 (11.3) 6 (10.2)
Transfer-entry 3001 patientse 5 (5.6) 4 (4.7) 5 (8.1) 3 (5.1)
Transfer-entry 3002 patientsf 21 (23.3) 20 (23.3) 8 (12.9) 10 (16.9)
84 mg 50 (55.6) 53 (61.6) 42 (67.7) 40 (67.8)
Direct-entry patients 12 (13.3) 11 (12.8) 8 (12.9) 2 (3.4)
Transfer-entry 3001 patientse 5 (5.6) 6 (7.0) 11 (17.7) 7 (11.9)
Transfer-entry 3002 patientsf 33 (36.7) 36 (41.9) 23 (37.1) 31 (52.5)
Dosing frequency at baseline
Weekly 37 (41.1) 41 (47.7) 51 (83.6) 43 (72.9)
Every other week 53 (58.9) 45 (52.3) 10 (16.4) 16 (27.1)
Missing 0 0 1 0
Abbreviations: MADRS, Montgomery-Åsberg Depression Rating scale;
MDD, major depressive disorder; PHQ-9, Patient Health Questionnaire 9;
SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin
reuptake inhibitor.
a Data are presented as number (percentage) of patients unless otherwise
indicated.
b Patients who achieved stable remission: 54 for esketamine nasal spray and
oral antidepressant and 56 for oral antidepressant and placebo nasal spray;
patients who achieved stable response: 31 for esketamine nasal spray and oral
antidepressant and 41 for oral antidepressant and placebo nasal spray.
c Patients who achieved stable remission: 36 for esketamine nasal spray and
oral antidepressant and 30 for oral antidepressant and placebo nasal spray;
patients who achieved stable response: 31 for esketamine nasal spray and oral
antidepressant and 18 for oral antidepressant and placebo nasal spray.
dDuring the optimization phase and before randomization.
e The 3001 indicates transferred from Janssen-sponsored fixed-dose
esketamine study TRD3001.15
f The 3002 indicates transferred from Janssen-sponsored flexible-dose
esketamine study TRD3002.12
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weeks among patients who achieved stable response. Me-
dian exposure to placebo during the maintenance phase was
10.2weeksamongpatientswhoachievedstable remissionand
10.1 weeks among those who achieved stable response.
Of the 90 patients who achieved stable remission in the
esketamineandantidepressant group, 40 (44.4%) received56
mg of esketamine on day 1 of the maintenance phase and 50
(55.6%) received 84mg, with 62 (68.9%) receiving treatment
every 2 weeks for most of the maintenance phase. A greater
proportionof the62patientswhoachieved stable response in
the esketamine and antidepressant group received thehigher
esketamine dose in the maintenance phase (56 mg: n = 20
[32.3%];84mg:n = 42[67.7%]),with34(54.8%)receivingtreat-
ment once weekly most of the time.
Efficacy Results
Overall, amongpatientswhoachievedstable remission, 24pa-
tients (26.7%) in theesketamineandantidepressantgroupand
39 patients (45.3%) in the antidepressant and placebo group
experienced a relapse event during the maintenance phase;
among thepatientswho achieved stable response (but not re-
mission), 16 patients (25.8%) in the esketamine and antide-
pressant group and 34 patients (57.6%) in the antidepressant
and placebo group experienced relapse (Table 2). Continued
treatment with esketamine and antidepressant significantly
delayed relapse compared with treatment with antidepres-
sant and placebo (patients who achieved stable remission:
HR,0.49;95%CI,0.29-0.84;P = .003,numberneeded to treat
[NNT], 6; patients who achieved stable response: HR, 0.30;
95% CI, 0.16-0.55: P < .001, NNT, 4). According to HR esti-
mates, treatment with esketamine and antidepressant de-
creasedrelapseriskby51%amongpatientswhoachievedstable
remissionandby70%amongpatientswhoachieved stable re-
sponse comparedwith antidepressant andplacebo (Figure 2).
In addition, in aposthoc analysis, esketamineandantidepres-
sant delayed relapse compared with antidepressant and pla-
cebo among patients who achieved stable remission and pa-
tients who achieved stable response combined (HR, 0.38;
95%CI, 0.26-0.57;P < .001). In a post hoc sensitivity analysis
for the primary end point, using a MADRS score cutoff of 10
for remission, the between-groupdifference remained statis-
tically significant (2-sided P = .005) (eTable 1 in Supple-
ment 2). Time to relapse for patients who achieved stable re-
mission was also assessed by study entry (direct vs transfer).
The HRs were 0.49 (95% CI, 0.27-0.90) for direct-entry pa-
tients and 0.45 (95%CI, 0.17-1.18) for transfer-entry patients.
Given the lowmediannumberofpatientsper site (2; range,
1-25), to further evaluate the effect of site on the estimation
of treatment effect (ie,HR), a post hoc sensitivity analysiswas
performedusing aCoxproportional hazards regressionmodel
by excluding one site at a time. On the basis of this analysis,
theHRwasestimated to range from0.42 to0.57,which is con-
sistent with the overall HR of 0.47 (unweighted).
Nineteenof the39 relapses inpatientswhoachievedstable
remission and who were switched to placebo nasal spray oc-
curred in the firstmonth after discontinuation of esketamine
treatment (6 byweek 2 and the remainder byweek 4), with 11
of these 19 early relapses occurring in patients who had re-
quiredweekly treatment administration in the last 4weeks of
the optimization phase before randomization (eFigure 1 in
Supplement 2).
After completing inductionandoptimization treatment (16
weeks total), in patients who achieved stable remission and
those who achieved stable response, there was separation in
MADRS total scores between patients randomized to con-
tinue vs discontinue esketamine treatment, each in the pres-
enceof antidepressant therapy,withMADRS total scoresbeing
lower over time for esketamine-treated patients. This separa-
tionwasmaintained in both patients who achieved stable re-
missionandthosewhoachievedstable response.MeanMADRS
total scoreover timeusing lastobservationcarried forwarddata
during the induction, optimization, andmaintenance phases
is presented in eFigure 2 in Supplement 2.
Table 2. Time to Relapse and Number of Patients
Who Remained Relapse Free in theMaintenance Phasea
Group
Esketamine Nasal
Spray and Oral
Antidepressant
Oral Antidepressant
and Placebo
Nasal Spray
Patients Who Achieved Stable Remission
No. assessed 90 86
No. (%) censored 66 (73.3) 47 (54.7)
No. (%) of relapses 24 (26.7) 39 (45.3)
25th Percentile (95% CI) 153.0 (105.0-225.0) 33.3 (22.0-48.0)
Median (95% CI) NE 273.0 (97.0 to NE)
75th Percentile (95% CI) NE NE
HR (95% CI)b 0.49 (0.29-0.84)
2-Sided P valuec .003
Patients Who Achieved Stable Response
No. assessed 62 59
No. (%) censored 46 (74.2) 25 (42.4)
No. (%) of relapses 16 (25.8) 34 (57.6)
25th Percentile (95% CI) 217.0 (56.0-635.0) 24.0 (17.0-46.0)
Median (95% CI) 635.0 (264.0-635.0) 88.0 (46.0-196.0)
75th Percentile (95% CI) 635.0 (NE) NE
HR (95% CI)d 0.30 (0.16-0.55)
2-Sided P valuee <.001
Abbreviations: HR, hazard ratio; NE, not estimable.
a Censoringwas done for patientswho remained relapse free at the endof the
study, definedby achieving the target number of relapse events, orwho
withdrewearlywithout relapse in themaintenancephase.Most censored
patients (ie,whenparticipationwas ended)were considered as administrative
basedon the study having reached its endpoint (ie, basedon the target number
of relapse events having been achieved and the study stopping). Only 13
(8patientswho achieved stable remission and5patientswho achieved stable
response) in the esketamine nasal spray andoral antidepressant group and 12
(9patientswho achieved stable remission and3patientswho achieved stable
response) in the oral antidepressant andplacebo groupwere censoredbecause
they discontinued themaintenancephase before having a relapse andbefore
the endof the study.25Data are basedonKaplan-Meier product-limit estimates.
bHR and CI are weighted estimates based onWassmer25 and calculated using
gsDesign andmvtnorm packages in R.
c Two-sided P value is based on the final test statistic, which is a weighted
combination of the log-rank test statistics calculated on the interim and final
analysis sets.
d Regression analysis of survival data based on Cox proportional hazards
regressionmodel with treatment as a factor.
e Log-rank test.
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Safety Results
The 5 most common AEs reported in the esketamine and an-
tidepressant group during the maintenance phase were dys-
geusia, vertigo, dissociation, somnolence, and dizziness
(Table 3).MostAEsweremild tomoderate, observedafterdos-
ing, and generally resolved in the sameday.No cases of respi-
ratory depression or interstitial cystitis were observed.
Nodeathswere reportedduring thestudy.SeriousAEscon-
sidered by the investigator as related to study drug were re-
ported for 6 patients in the esketamine and antidepressant
group (autonomic nervous system imbalance, disorienta-
tion, hypothermia, lacunar stroke [ie, ischemic lesion, day 1,
6 hours after dosing], sedation, simple partial seizures [day 5,
45minutes after dosing; no seizure history], and suicidal ide-
ation) during the induction phase. No seriousAEs considered
as related to esketamine were reported during the optimiza-
tion or maintenance phases.
Sevenpatientsexperienced1ormoreAEsduring themain-
tenance phase, leading to discontinuation of the intranasal
study drug; 4 (2.6%) of 152 were in the esketamine and anti-
depressant group (worsening depression, 3 patients; anxiety
and confusional state [transient], 1 patient) and 3 (2.1%) of 145
were in the antidepressant and placebo group (worsening de-
pression for each).
Transientbloodpressure increaseswereobservedwithes-
ketamineon treatmentdays; themaximumvaluewas reached
at 40 minutes after the start of administration in most cases
and typically returned to the predose range by 1.5 hours after
administration (eFigure 3 in Supplement 2). Few patients ex-
periencedtreatment-emergent transienthypertension,defined
Figure 2. Kaplan-Meier Estimates of Time to Relapse
0
100
80
Pa
tie
nt
s W
ith
ou
t R
el
ap
se
, %
60
40
20
0
100
80
Pa
tie
nt
s W
ith
ou
t R
el
ap
se
, %
60
40
20
B Patients who achieved stable response
No. at risk
Esketamine nasal spray
and oral antidepressant
Oral antidepressant and
placebo nasal spray
0
90
86
84
69
74
52
58
41
53
34
39
28
31
22
25
19
20
12
14
10
10
7
8
4
7
3
7
3
6
3
5
3
2
3
1
2
1
2
1
1
1
0
0
0
62 62 49 38 35 31 26 20 15 13 11 9 7 6 6 6 5 2 2 2 2 1 1 0
59 44 35 26 19 17 13 9 4 3 2 2 2 2 1 1 1 1 0 0 0 0 0 0
92
Hazard ratio (95% CI) = 0.49 (0.29-0.84)
Hazard ratio (95% CI) = 0.30 (0.16-0.55)
No. at risk
Esketamine nasal spray
and oral antidepressant
Oral antidepressant and
placebo nasal spray
Esketamine nasal spray
and oral antidepressant
Esketamine nasal spray
and oral antidepressant
Oral antidepressant and
placebo nasal spray
Patients who achieved stable remissionA
4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88
0 92
Time, wk
Time, wk
4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88
Oral antidepressant and
placebo nasal spray
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response. Themost common cause
of censoring participants was based
on being relapse free at study end
(see Table 2 legend). Vertical lines
indicate censored observations.
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as a systolic blood pressure of 180 mm Hg or higher and/or a
diastolic blood pressure of 110 mm Hg or higher (ie, systolic
hypertension: 1 [0.7%] esketamine-treated patient and 0 an-
tidepressant- and placebo-treated patients; diastolic hyper-
tension: 2 [1.3%] esketamine-treated patients and 0 antide-
pressant-andplacebo-treatedpatients)during themaintenance
phase. No clinically significant change in electrocardio-
graphic findings was observed during the study.
Most direct-entry patients (362 [85.4%]) had baseline
C-SSRS scores of 0, indicating no suicidal ideation or behav-
ior. Of those patients treated with esketamine and oral anti-
depressant who reported no suicidal ideation or behavior at
baseline, 42 (11.6%) had a higher postbaseline score (maxi-
mum C-SSRS score of 1 [n = 35], 2 [n = 3], 3 [n = 2], 5 [n = 1],
and8 [n = 1]) during theopen-label inductionphase; 22 (5.7%)
(direct- and transfer-entry patients) had a higher postbase-
line score (maximumC-SSRS score of 1 [n = 17], 2 [n = 3], and
3 [n = 2]) in the optimization phase; and 3 (2.4%) had ahigher
postbaseline score (maximum C-SSRS score of 1 [n = 2] and 4
[n = 1]) comparedwith6patients (4.5%) receiving antidepres-
sant and placebo (maximum C-SSRS score of 1 [n = 6]) in the
maintenancephase.On the basis of theC-SSRS, therewereno
reports of suicidal behavior in the optimization or mainte-
nance phases. None of the patients who experienced relapse
had a significant elevation in C-SSRS score (ie, the most se-
verepostbaseline scorewas2 forpatientswhoexperienced re-
lapse in theesketamineandantidepressant groupand3 forpa-
tients who experienced relapse in the antidepressant and
placebo group).
Present-state dissociative symptoms, as measured by
CADSS(eFigure4 inSupplement2),beganshortlyafter thestart
of esketamine treatment, peaked at 40 minutes, and gener-
ally resolved by 1.5 hours. The magnitude of symptoms at-
tenuated with repeated administrations over time in the in-
ductionphase,witha relatively lowmagnitude reported in the
optimization andmaintenancephase.No symptomsorAEsof
psychosis were observed.
Of note, 1 patient received 1 dose of ketamine (10 mg in-
travenously) during the study for the treatment of an AE of
nephrolithiasis, but no AEs were reported by any participant
related to use or abuse of ketamine. No evidence of a distinct
withdrawal syndromewas observed during the 2weeks after
cessation of esketamine nasal spray as assessed by the 20-
item PhysicianWithdrawal Checklist.
Discussion
In this first study, toourknowledge, of esketaminenasal spray
for relapse prevention in patients with TRD, continued treat-
ment with esketamine and an antidepressant demonstrated
clinically meaningful and statistically significant superiority
compared with antidepressant and placebo in delaying re-
lapse in patients who had achieved stable remission or stable
response after 16weeks of treatmentwith esketamine and an
antidepressant. No major difference in efficacy was seen by
direct- or transferred-entry status.
One concern often cited in interpretation of randomized
withdrawal studies is that the increased rate of depression
observed after switching to placebo is a pharmacologic con-
sequence of antidepressant withdrawal.26 A high relapse
rate early in the withdrawal period could indicate a possible
withdrawal or rebound effect. In this study, although there
were a high number of relapses in the first month in those
switched to placebo nasal spray, it is unlikely that a pharma-
cologic withdrawal effect contributed given that the
decrease in esketamine plasma concentrations is rapid for
the initial 2 to 4 hours and more gradual thereafter (mean
terminal half-life, 7-12 hours), with steady state never
reached with intermittent dosing. Moreover, this high rate of
early relapse is similar to that observed after cessation of
electroconvulsive therapy.27 There are no known rebound
effects after electroconvulsive therapy discontinuation.
The high rates of early relapse after esketamine discontinua-
tion and those observed by Rush et al3 for patients in the
Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study at level 3 or 4 (ie, who had failed 2 and 3
prior antidepressant treatments, respectively) more likely
reflect a greater vulnerability to relapse among patients with
Table 3. Most Frequently Reported Adverse Events in theMaintenance
Phase in PatientsWho Achieved Stable Remission
and ThoseWho Achieved Stable Responsea
Adverse Event
No. (%) of Patients
Esketamine
Nasal Spray
and Oral
Antidepressant
(n = 152)
Oral
Antidepressant
and Placebo
Nasal Spray
(n = 145)
Dysgeusia 41 (27.0) 10 (6.9)
Vertigo 38 (25.0) 8 (5.5)
Dissociation 35 (23.0) 0
Somnolence 32 (21.1) 3 (2.1)
Dizziness 31 (20.4) 7 (4.8)
Headache 27 (17.8) 14 (9.7)
Nausea 25 (16.4) 1 (0.7)
Vision blurred 24 (15.8) 1 (0.7)
Hypoesthesia oral 20 (13.2) 0
Anxiety 12 (7.9) 5 (3.4)
Nasal discomfort 11 (7.2) 4 (2.8)
Paresthesia 11 (7.2) 0
Viral upper respiratory
tract infection
11 (7.2) 12 (8.3)
Blood pressure increased 10 (6.6) 5 (3.4)
Dizziness postural 10 (6.6) 3 (2.1)
Sedation 10 (6.6) 1 (0.7)
Vomiting 10 (6.6) 1 (0.7)
Confusional state 9 (5.9) 0
Diplopia 9 (5.9) 0
Hypoesthesia 9 (5.9) 0
Paresthesia oral 8 (5.3) 1 (0.7)
Throat irritation 8 (5.3) 1 (0.7)
a Adverse events are listed in decreasing order based on incidence within the
esketamine plus antidepressant group and in alphabetical order for events
with the same incidence. The incidence was 5% or greater in either
treatment group.
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TRD during maintenance treatment with an antidepressant
alone.
In recognition of interindividual variability, the MADRS-
based treatment algorithm individualizeddosing frequency to
the lowest frequency thatmaintained remission or response.
Dosing frequencywas reduced toonceevery2weeks if thepa-
tient had achieved remission (ie, MADRS score ≤12), whereas
those unable to achieve ormaintain remissionwere assigned
to a weekly dosing frequency. Of note, more than half of the
patients who experienced relapse during the first month af-
ter discontinuation of esketamine treatment requiredweekly
dosing to sustain remission, reflecting the higher vulnerabil-
ity in this subpopulation. Taken together, the evidence sug-
gests that relapses seen in the first weeks after discontinuing
esketamine treatment are likely attributable to more vulner-
able patients and not awithdrawal or rebound phenomenon.
Noneworunexpected safety concernwasobserved in this
long-term study of esketamine nasal spray administered
weekly or every 2 weeks. Results were consistent with previ-
ous findings fromcompleted short-term (4-week) phase2 and
3 studies.10,12,15
Limitations
Study limitations include the fact that esketaminehas known
transient dissociative and sedative effects that are difficult to
blind; these symptoms could have biased the staff who ob-
served treatment administration. To ensure unbiased effi-
cacy evaluation, independent, remote, blinded MADRS rat-
ers assessed treatment response throughout this study. In
addition, a post hoc analysis assessed participants random-
ized todiscontinue intranasal esketamine treatmentwhosub-
sequently experienced relapse in the first 4weeksof themain-
tenance phase (n = 19). A sensitivity analysis, performed by
censoring the patients who experienced relapse and showed
a clear change in CADSS score before and after randomization
(n = 3), resulted in an HR of 0.50 (95% CI, 0.30-0.84) with a
2-sidedP = .008 (consistentwith theprimary analysis), based
onanunweightedCoxproportional hazards regressionmodel
and log rank test.
Conclusions
This study demonstrated that, after 16 weeks of initial treat-
ment, continued treatmentwith esketamine plus antidepres-
sant leads to significant, clinically meaningful superiority
compared with an antidepressant plus placebo for relapse
prevention among patients with TRD and provides further
safety data supporting a positive benefit-risk ratio of long-
term treatment.
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